MET and neoplasm: To elucidate the role of c-Met signaling and its involvement with HER family signaling as a cancer co-driver, a new test was developed based on the principle of tumor cell impedance alterations from hypersignaling as described previously for patients that we demonstrated do not have overexpressed receptors.